These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 14676787)

  • 21. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.
    Casserly LF; Fadia A; Sanchorawala V; Seldin DC; Wright DG; Skinner M; Dember LM
    Kidney Int; 2003 Mar; 63(3):1051-7. PubMed ID: 12631087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
    Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
    Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
    Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].
    Imataki O; Aoyama T; Tamai Y; Kawakami K
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1633-6. PubMed ID: 17940379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
    Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
    Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
    Sanchorawala V; Hoering A; Seldin DC; Finn KT; Fennessey SA; Sexton R; Mattar B; Safah HF; Holmberg LA; Dean RM; Orlowski RZ; Barlogie B
    Bone Marrow Transplant; 2013 Nov; 48(12):1537-42. PubMed ID: 23852321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
    Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Kumar SK; Leung N; Lust J; Rajkumar SV; Russell SJ; Suman VJ; Le-Rademacher JG; Hogan WJ
    Cancer; 2016 Jul; 122(14):2197-205. PubMed ID: 27142462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
    Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
    Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.
    Rosengren S; Mellqvist UH; Nahi H; Forsberg K; Lenhoff S; Strömberg O; Ahlberg L; Linder O; Carlson K
    Bone Marrow Transplant; 2016 Dec; 51(12):1569-1572. PubMed ID: 27694943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
    Skinner M; Sanchorawala V; Seldin DC; Dember LM; Falk RH; Berk JL; Anderson JJ; O'Hara C; Finn KT; Libbey CA; Wiesman J; Quillen K; Swan N; Wright DG
    Ann Intern Med; 2004 Jan; 140(2):85-93. PubMed ID: 14734330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
    Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
    J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.
    Seldin DC; Anderson JJ; Skinner M; Malek K; Wright DG; Quillen K; Finn K; Oran B; Sanchorawala V
    Blood; 2006 Dec; 108(12):3945-7. PubMed ID: 16926284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
    Cibeira MT; Sanchorawala V; Seldin DC; Quillen K; Berk JL; Dember LM; Segal A; Ruberg F; Meier-Ewert H; Andrea NT; Sloan JM; Finn KT; Doros G; Blade J; Skinner M
    Blood; 2011 Oct; 118(16):4346-52. PubMed ID: 21828140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
    Moreau P; Facon T; Attal M; Hulin C; Michallet M; Maloisel F; Sotto JJ; Guilhot F; Marit G; Doyen C; Jaubert J; Fuzibet JG; François S; Benboubker L; Monconduit M; Voillat L; Macro M; Berthou C; Dorvaux V; Pignon B; Rio B; Matthes T; Casassus P; Caillot D; Najman N; Grosbois B; Bataille R; Harousseau JL;
    Blood; 2002 Feb; 99(3):731-5. PubMed ID: 11806971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma.
    Weaver CH; Zhen B; Schwartzberg LS; Leff R; Magee M; Geier L; Deaton K; Lewkow L; Buckner CD
    Bone Marrow Transplant; 1998 Aug; 22(3):245-51. PubMed ID: 9720737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
    Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
    Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.